SeaStar Medical said the FDA has determined that its pediatric QUELIMMUNE surveillance registry has met the post-approval study requirements tied to the device’s original approval. The decision removes the registry’s research infrastructure as a barrier for hospitals that want to use the therapy, while SeaStar plans to continue enrolling patients at centers that choose to participate.
QUELIMMUNE is used for certain critically ill children with sepsis-associated acute kidney injury who are receiving renal replacement therapy. The FDA decision closes a required study obligation; it does not establish that the device’s effectiveness has been demonstrated.
Key details
-
Registry results: Data presented at ASN Kidney Week 2026 showed 90-day survival of 65.1% among 43 children treated with QUELIMMUNE, compared with 47.5% among 196 patients in clinically aligned cohorts drawn from the Kids’ Inpatient Database. The reported difference was statistically significant (P=0.043).
-
Other reported outcomes: SeaStar said the analysis also found statistically significant improvements in in-hospital and 60-day survival for treated patients compared with the database cohorts. The company did not provide those survival rates in the announcement.
-
Study limitations and safety: The comparison was with database cohorts, not a randomized control group. SeaStar reported no device-related adverse events among patients in the registry. The therapy’s known risks include reactions such as low blood pressure, low body temperature, rapid heart rate, high blood sugar and low platelet counts, as well as potential blood loss or complications involving the extracorporeal circuit.
-
Access and continued data collection: Hospitals can use QUELIMMUNE without the research infrastructure required by the SAVE Registry, according to SeaStar. The company will continue voluntary enrollment at participating centers to gather real-world data.
-
Approved use: QUELIMMUNE was approved in February 2024 under a Humanitarian Device Exemption for patients aged 22 or younger who weigh at least 10 kilograms, have acute kidney injury with sepsis or a septic condition, and are receiving antibiotics and renal replacement therapy in an intensive care unit.
What changes for investors
The regulatory milestone clears the required post-approval study obligation and, as SeaStar describes it, allows more hospitals to use the therapy without joining the registry. It does not amount to a newly disclosed expansion of QUELIMMUNE’s approved use. The device was approved based on safety and probable benefit; its effectiveness for this use has not been demonstrated.